GlassScriptPhysician profile
Luis Carlos Quintero
NPI 1710073648
$10,548.74
in general payments reported to CMS, 2019-2025
46 companies · $2,296 in 2025
The $2,296 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,616 · 2020: $593 · 2021: $1,191 · 2022: $1,648 · 2023: $1,018 · 2024: $1,187 · 2025: $2,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,450 · Travel and Lodging: $51.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,449.62 |
| Travel and Lodging | $51.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $1,045.90 | 2019-2025 | Omnipod |
| Medtronic, INC. | $1,005.66 | 2021-2025 | Minimed 780g, Minimed 770g, Mycarelink |
| Sanofi-Aventis U.S. LLC | $982.28 | 2019-2022 | |
| Novo Nordisk INC | $856.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $851.16 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $752.56 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Corcept Therapeutics | $742.01 | 2021-2025 | Korlym |
| Pfizer INC. | $644.30 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $467.42 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $403.02 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.55 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Medtronic Minimed, INC. | $246.96 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $213.05 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Acadia Pharmaceuticals INC | $190.51 | 2022-2025 | Nuplazid |
| Ascensia Diabetes Care US INC. | $161.16 | 2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $152.70 | 2019 | |
| Abbvie INC. | $145.88 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.50 | 2024 | Caplyta |
| Eisai INC. | $116.30 | 2021 | |
| Amgen INC. | $104.61 | 2024-2025 | Tepezza, Repatha, Prolia |
| Neurocrine Biosciences, INC. | $104.09 | 2024 | Ingrezza |
| Cequr Corporation | $96.46 | 2022-2024 | Cequr Simplicity |
| Abbott Laboratories | $87.21 | 2021-2025 | Freestyle Libre 3 |
| Madrigal Pharmaceuticals | $76.64 | 2025 | Rezdiffra |
| Esperion Therapeutics, INC. | $65.41 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $60.21 | 2019 | |
| Radius Health, INC. | $43.45 | 2019-2021 | |
| Horizon Therapeutics Plc | $42.00 | 2021-2022 | |
| Amarin Pharma, INC. | $40.80 | 2021-2022 | |
| Sequel Med Tech, LLC | $39.95 | 2025 | Twiist |
| Zoll Medical Corporation | $35.31 | 2024 | Defibrillator |
| Lifescan, INC. | $34.20 | 2022 | |
| Valeritas, INC. | $30.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.45 | 2025 | |
| Sumitomo Pharma America, INC. | $25.40 | 2024 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $24.96 | 2022 | |
| Covidien LP | $24.64 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.14 | 2021 | |
| Ibsa Pharma INC. | $21.82 | 2023 | Licart, Tirosint |
| Exact Sciences Corporation | $21.36 | 2023 | Cologuard Collection Kit |
| Abiomed | $20.70 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $19.31 | 2019 | |
| Ardelyx, INC. | $18.83 | 2024 | Ibsrela |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Quintero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.